Back to search results

Long-Term Safety Study for Century Therapeutics Cellular Therapy

This study is for people who have previously received a cellular therapy product from Century Therapeutics for blood cancers (hematological malignancy) or solid tumors. It's an observational study, meaning you won't receive new treatment as part of this study. Instead, researchers will collect information about your long-term safety and survival, looking for any side effects (adverse events) that might appear after treatment with these cellular products. The main goal is to track any special side effects for up to 180 months (15 years). You can join if you are 18 or older, have given written consent, and completed or left an earlier Century Therapeutics cellular therapy trial.

Study design
This is an observational study designed to enroll 375 participants. It is not a randomized or blinded study.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 180 months (15 years) to track any special adverse events.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05768269

A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

Recruiting
Not specifiedAges 18+Observational
Century Therapeutics, Inc.
~375 participants
Updated 2025-06-25 on ClinicalTrials.gov
What's tested:No Intervention

At a glance

Recruiting sites
4 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants With any Adverse Events of Special Interest (AESI)
Measured over Up to 180 months

Conditions

Hematological Malignancy
Solid Tumor Malignancy

Explore related trials

Hematologic NeoplasmSolid Neoplasm

NCT05768269

Where you'd take part

This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizonastudy coordinator listed

    Not yet recruiting

  • Corewell Health

    Grand Rapids, Michiganstudy coordinator listed

    Not yet recruiting

  • Levine Cancer Institute

    Charlotte, North Carolinastudy coordinator listed

    Recruiting

  • Swedish Cancer Institute

    Seattle, Washingtonstudy coordinator listed

    Recruiting

  • University of Cincinnati Medical Center

    Cincinnati, Ohiostudy coordinator listed

    Recruiting

  • University of Maryland Medical Center

    Baltimore, Marylandstudy coordinator listed

    Recruiting

  • University of Southern California - Norris Comprehensive Cancer Center

    Los Angeles, Californiastudy coordinator listed

    Not yet recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Century Therapeutics Clinical Team
[email protected]
8885067670
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participant has provided written informed consent prior to any long-term follow-up (LTFU) study-specific procedures.
Participants received at least one treatment with a cellular therapy product in an eligible index trial.
Participant was withdrawn, early discontinued or completed an eligible index trial.
Participant is willing and able to comply with scheduled visits, study plan, and other study procedures.

What this trial measures

  • Number of Participants With any Adverse Events of Special Interest (AESI)Up to 180 months